Clinical Trial Update: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) [Phase 2]

View source ↗

Summary

This update reports results from the CheckMate 650 Phase 2 trial evaluating nivolumab plus ipilimumab, ipilimumab alone, and cabazitaxel in men with metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-04-24